Anti-platelet therapy with acetylsalicylic acid (ASA) is recommended in patients > 60 years or in the presence of either the driver mutation JAK2-V617F or uncontrolled cardiovascular risk factors or a history of thrombosis provided there are no risk factors for hemorrhage [11, 94]. The gene discussed is JAK2; the disease is deep vein thrombosis.